Study Schema.
baseline hepatic steatosis, dyslipidemias
DYSLIPIDEMIAS
This schema reflects the basket trial approach taken in this Phase 1 study AROANG1001 to evaluate early proof of-concept, in which healthy participants (HPs) and patients with various dyslipidemias were enrolled. In this report, we present the key results from this study showing the safety, tolerability, and pharmacodynamic effects of single ascending doses of ARO-ANG3 in HPs and multiple doses of ARO-ANG3 in both HPs and a cohort of patients with baseline hepatic steatosis. These cohorts are shown in red boxes.
